Portal de investigación
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
BAYER CONSUMER CARE AG
Cita
A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer. (BAY1841788/21492). BAYER CONSUMER CARE AG. 2023IP:ANTONIO CONDE MORENO.